微小RNA调控 PD-L1表达在妇科肿瘤中的研究进展

摘要/Abstract

摘要： 微小RNA (miRNA)通过加速mRNA降解或阻断mRNA翻译来调控相应的靶基因表达。免疫系统作为一种外在的肿瘤抑制因子，通过破坏正在发展的肿瘤或抑制肿瘤扩张来影响肿瘤发生进展。近年来，肿瘤免疫治疗作为肿瘤临床研究的热点正在迅猛发展，免疫检查点抑制剂如PD-1以及其配体PD-L1抑制剂，已在妇科恶性肿瘤中取得了突破性的进展。目前，已有研究发现肿瘤中PD-L1的表达可能受多种miRNA的直接调控，miRNA可能通过肿瘤微环境中免疫状态改变、逆转肿瘤化疗耐药、调节肿瘤的免疫抵抗、诱导杀伤细胞靶向杀伤作用等多个方面调控 PD-L1表达，从而影响肿瘤发展的病理过程。miRNA调控 PD-L1表达在妇科肿瘤中的研究多集中在宫颈癌、卵巢癌及子宫内膜癌等常见妇科肿瘤。本研究拟综述当前微小RNA调控 PD-L1表达在妇科肿瘤中的发展趋势和研究重点，以期为妇科肿瘤患者的临床治疗提供可靠的理论依据。

关键词: font-size:medium, ">微小RNA；PD-1；PD-L1；宫颈癌；卵巢癌；子宫内膜癌

Abstract: MicroRNAs (miRNAs) regulate target gene expression by accelerating mRNA degradation or blocking mRNA translation. Immune system， as an external tumor suppressor， affects the occurrence and progression of tumors by destroying tumors that are developing or inhibiting tumor expansion.In recent years， tumor immunotherapy is developing rapidly as a hotspot of tumor clinical research. Immune checkpoint inhibitors include programmed cell death-1 (PD-1) and its PD-L1 inhibitors have made a breakthrough in gynecological malignancies. At present， it has been found that the expression of PD-L1 in tumors may be directly regulated by multiple miRNAs and miRNA may regulate PD-L1 expression by changing the immune status in tumor microenvironment， reversing tumor chemotherapy resistance， regulating tumor immune resistance， and inducing targeted killing effect of killer cells， thus affecting the pathological process of tumor development.The study on miRNA regulating PD-L1 expression in gynecological tumors mainly focuses on cervical cancer， ovarian cancer， endometrial cancer and other common gynecological tumors.This study reviewed the current development trend and research focus of microRNA-regulated PD-L1 expression in gynecological tumors， in order to provide reliable theoretical basis for clinical treatment of gynecological tumors.

Key words: font-size:medium, ">microRNA；PD-1；PD-L1；Cervical cancer；Ovarian cancer；Endometrial carcinoma

中图分类号:

徐洁欢, 陈建林. 微小RNA调控 PD-L1表达在妇科肿瘤中的研究进展[J]. 中国医药导刊, 2023, 25(1): 39-44.

XU Jiehuan, CHEN Jianlin. Research Progress on the Regulation of PD-L1 Expression by microRNA in Gynecological Tumors[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(1): 39-44.

参考文献

[1]He R，Zhu B，Liu J，et al.Women′s cancers in China： a spatio-temporal epidemiology analysis[J].BMC Womens Health，2021，21(1)：116.
     [2]Cao W，Chen HD，Yu YW，et al.Changing profiles of cancer burden worldwide and in China： a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl)，2021，134(7)：783-791.
     [3]赵安，郭利伟，陈爱萍，等.肿瘤外泌体：诊断与治疗[J].中国肿瘤， 2017，(3)：190-194.
     [4]Zhou C，Wei W，Ma J，et al.Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels[J].Mol Ther，2021，29(4)：1512-1528.
     [5]Chin S，Kong W， Lian Q， et al.A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from critically-ill cancer patients without the need for apheresis or peripheral mobilization[J].Cytotherapy，2019，21 (5)：S88.
     [6]Wang C，Kuang L，Han L.MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the PD-1/PD-L1 signaling pathway[J].J Reprod Immunol，2021，143：103265.
     [7]Muoz-Fontela C，Mandinova A，Aaronson SA，et al. Emerging roles of p53 and other tumour-suppressor genes in immune regulation[J].Nat Rev Immunol，2016，16：741-750.
     [8]Dong P，Xiong Y，Yu J，et al.Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer[J].Oncogene，2018，37(39)：5257-5268.
     [9]Zhang Y，Qiu S，Guo Y，et al.Diagnostic value of vaginal microecology，serum miR-18a， and PD-L1 for identifying HPV-positive cervical cancer[J].Technol Cancer Res Treat，2021，20：1533033821995281.
     [10]Lai Y，Zhou B，Tan Q，et al.LINC00116 enhances cervical cancer tumorigenesis through miR-106a/c-Jun pathway[J].J Cell Biochem，2020，121(3)：2247-2257.
     [11]Liu S，Guo C，Wang J，et al. ANXA11 regulates the tumorigenesis， lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun[J].Oncotarget，2016， 7(13) ： 16297-16310..
     [12]王根生，王悦. 卵巢癌微环境与化疗耐药发生相关的研究进展[J].肿瘤，2020， 40(1)：68-75.
     [13]Smith RA，Andrews KS，Brooks D，et al.Cancer screening in the United States，2019： a review of current American cancer society guidelines and current issues in cancer screening[J].CA Cancer J Clin，2019，69(3)：184-210.
     [14]Mandai M，Hamanishi J，Abiko K，et al.Anti-PD-L1/PD-1 immune therapies in ovarian cancer： basic mechanism and future clinical application[J].Int J Clin Oncol，2016，21：456-461.
     [15]Pan G，Liu Y，Shang L，et al.EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J].Cancer Commun (Lond)，2021，41(3)：199-217.
     [16]Zuo Y，Zheng W，Liu J，et al.MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells[J].Neoplasma，2020，67(1)：93-101.
     [17]Sheng Q，Zhang Y，Wang Z，et al.Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells[J].Clin Exp Immunol，2020，200(1)：45-52.
     [18]Morad G，Helmink BA，Sharma P，et al.Hallmarks of response， resistance， and toxicity to immune checkpoint blockade[J].Cell，2021，184(21)：5309-5337.
     [19]Xu S，Tao Z，Hai B，et al.miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint[J].Nat Commun，2016，7：11406.
     [20]Li K，Shi H，Zhang B，et al.Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer[J].Signal Transduct Target Ther，2021，6(1)：362.
     [21]Shi Y，Geng D，Zhang Y，et al. LATS2 inhibits malignant behaviors of glioma cells via inactivating YAP[J].J Mol Neurosci，2019，68：38-48.
     [22]Feng S，Sun H，Zhu W.MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway[J].Clin Transl Oncol，2021，23(3)：450-458.
     [23]Duan M，Fang M，Wang C，et al.LncRNA EMX2OS induces proliferation， invasion and sphere formation of ovarian cancer cells via regulating the miR-654-3p/AKT3/PD-L1 axis[J].Cancer Manag Res，2020，12：2141-2154.
     [24]Aichen Z，Kun W，Xiaochun S，et al.LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p[J].Apoptosis，2021，26(5-6)：348-360.
     [25]Zhao Y，Hong L.lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-κB signaling pathway[J].Cancer Biother Radiopharm，2021，36(2)：202-210.
     [26]Liu Z，Zhu Y，Li F，et al. GATA1-regulated JAG1 promotes ovarian cancer progression by activating notch signal pathway[J].Protoplasma，2020，257：901-910.
     [27]Li Y，Zhai Y，Chen Y.GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p[J].J Ovarian Res，2021，14(1)：108.
     [28]Wang L.Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer： a systematic review， meta-analysis and bioinformatics study[J].J Ovarian Res，2019，12(1)：37.
     [29]Anastasiadou E， Messina E， Sanavia T，et al. MiR-200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of β-Catenin and c-Myc[J].Cells，2021，10(3)：519.
     [30]Garcia-Diaz A， Shin DS， Moreno BH，et al.Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression[J].Cell Rep，2017，19(6)：1189-1201.
     [31]Koukourakis MI，Kontomanolis E，Sotiropoulou M，et al. Increased soluble PD-L1 levels in the plasma of patients with epithelial ovarian cancer correlate with plasma levels of miR34a and miR200[J].Anticancer Res，2018，38(10)：5739-5745.
     [32]Gottlieb CE，Mills AM，Cross JV，et al. Inoma：a comparison of matched primary and metastatic tumors[J].Gynecol Oncol，2017，144(3)：607-612.
     [33]中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南（2021年版）[J].中国癌症杂志，2021， 6(31)：501-512.
     [34]Delangle R，De Foucher T，Larsen AK，et al. The use of microRNAs in the management of endometrial cancer： a meta-analysis[J].Cancers (Basel)，2019，11(6)：832.
     [35]Zhou H，Chen L，Qin M，et al. An miRNA signature associated with tumor mutation burden in endometrial cancer[J].Biosci Rep，2020，40(11)：BSR20203398.
     [36]Zhang XH，Hu P，Xie YQ，et al. Long noncoding RNA HOTAIR promotes endometrial carcinoma cell proliferation by binding to PTEN via the activating phosphatidylinositol 3-Kinase/Akt signaling pathway[J]. Mol Cell Biol，2019，39(23)：e00251-e00219.
     [37]Xu J，Lin DI.Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas[J].PLoS One，2018，13(7)：e0199688.
     [38]Liu Y，Chang Y，Cai YX.Inhibition of Lnc-OC1 induced cell apoptosis and decreased cell viability by releasing miR-34a and inhibiting PD-L1 in endometrial carcinoma[J].Reprod Sci，2020，27(10)：1848-1856.

快速检索引用检索图表检索高级检索